See more : IMV Corporation (7760.T) Income Statement Analysis – Financial Results
Complete financial analysis of AddLife AB (publ) (0REZ.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AddLife AB (publ), a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Tantalus Systems Holding Inc. (TNTLF) Income Statement Analysis – Financial Results
- Onward Medical N.V. (ONWD.BR) Income Statement Analysis – Financial Results
- GAIL (India) Limited (GAILF) Income Statement Analysis – Financial Results
- The Erawan Group Public Company Limited (ERW.BK) Income Statement Analysis – Financial Results
- Conart Engineers Limited (CONART.BO) Income Statement Analysis – Financial Results
AddLife AB (publ) (0REZ.L)
About AddLife AB (publ)
AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments. This segment also offers support, maintenance, advice, and training services. The Medtech segment provides medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, and nose and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities. It operates in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.69B | 9.08B | 7.99B | 5.27B | 3.48B | 2.48B | 2.33B | 1.94B | 1.56B | 1.72B | 983.50M | 906.50M |
| Cost of Revenue | 6.09B | 5.66B | 5.14B | 3.45B | 2.28B | 1.59B | 1.49B | 1.27B | 1.01B | 1.11B | 608.50M | 553.30M |
| Gross Profit | 3.60B | 3.43B | 2.86B | 1.82B | 1.20B | 889.80M | 840.90M | 670.00M | 547.70M | 609.10M | 375.00M | 353.20M |
| Gross Profit Ratio | 37.16% | 37.73% | 35.74% | 34.48% | 34.44% | 35.86% | 36.04% | 34.57% | 35.06% | 35.36% | 38.13% | 38.96% |
| Research & Development | 167.00M | 81.00M | 33.50M | 23.90M | 24.30M | 19.50M | 17.60M | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 588.00M | 542.00M | 388.10M | 272.90M | 232.50M | 157.00M | 143.10M | 112.90M | 103.20M | 81.80M | 55.30M | 54.50M |
| Selling & Marketing | 2.48B | 2.13B | 1.49B | 873.60M | 777.10M | 557.10M | 524.00M | 413.60M | 344.20M | 391.80M | 215.60M | 201.60M |
| SG&A | 3.07B | 2.67B | 1.87B | 1.15B | 1.01B | 714.10M | 667.10M | 528.00M | 447.40M | 473.60M | 270.90M | 256.10M |
| Other Expenses | -219.00M | -130.00M | -34.10M | -28.40M | -33.60M | 7.60M | 100.00K | 0.00 | 400.00K | 20.90M | 200.00K | 300.00K |
| Operating Expenses | 3.01B | 2.62B | 1.87B | 1.14B | 1.00B | 723.10M | 668.70M | 529.90M | 446.30M | 466.40M | 270.40M | 255.60M |
| Cost & Expenses | 9.10B | 8.28B | 7.01B | 4.60B | 3.28B | 2.31B | 2.16B | 1.80B | 1.46B | 1.58B | 878.90M | 808.90M |
| Interest Income | 9.00M | 9.00M | 900.00K | 800.00K | 900.00K | 400.00K | 300.00K | 5.90M | 400.00K | 1.30M | 1.20M | 1.70M |
| Interest Expense | 288.00M | 112.00M | 56.90M | 17.00M | 12.40M | 7.20M | 8.00M | 0.00 | 6.60M | 8.70M | 2.60M | 3.10M |
| Depreciation & Amortization | 919.00M | 722.00M | 478.40M | 274.20M | 233.30M | 99.10M | 87.50M | 58.40M | 43.50M | 21.90M | 24.80M | 29.80M |
| EBITDA | 1.55B | 1.45B | 1.46B | 951.00M | 428.00M | 264.80M | 254.40M | 206.70M | 150.30M | 130.30M | 128.10M | 130.50M |
| EBITDA Ratio | 15.96% | 15.79% | 18.26% | 17.94% | 12.28% | 10.63% | 10.85% | 10.24% | 9.39% | 9.63% | 13.17% | 14.36% |
| Operating Income | 585.00M | 808.00M | 996.30M | 672.50M | 196.20M | 167.70M | 165.90M | 140.10M | 106.30M | 142.70M | 103.90M | 98.60M |
| Operating Income Ratio | 6.04% | 8.89% | 12.47% | 12.75% | 5.64% | 6.76% | 7.11% | 7.23% | 6.80% | 8.28% | 10.56% | 10.88% |
| Total Other Income/Expenses | -246.00M | -206.00M | -69.00M | -13.50M | -13.90M | -9.70M | -8.30M | -5.90M | -6.10M | -2.40M | -1.50M | -1.00M |
| Income Before Tax | 339.00M | 602.00M | 927.20M | 659.00M | 182.30M | 158.00M | 157.60M | 142.20M | 100.20M | 135.30M | 102.40M | 97.60M |
| Income Before Tax Ratio | 3.50% | 6.63% | 11.60% | 12.50% | 5.24% | 6.37% | 6.75% | 7.34% | 6.41% | 7.85% | 10.41% | 10.77% |
| Income Tax Expense | 147.00M | 119.00M | 206.60M | 139.30M | 40.00M | 28.70M | 37.30M | 30.40M | 22.40M | 33.30M | 24.10M | 23.20M |
| Net Income | 190.00M | 480.00M | 719.00M | 517.80M | 140.60M | 129.30M | 120.30M | 111.80M | 77.80M | 102.00M | 78.00M | 73.80M |
| Net Income Ratio | 1.96% | 5.28% | 9.00% | 9.82% | 4.04% | 5.21% | 5.16% | 5.77% | 4.98% | 5.92% | 7.93% | 8.14% |
| EPS | 1.56 | 3.94 | 6.02 | 4.62 | 1.27 | 1.29 | 1.18 | 1.16 | 0.99 | 1.09 | 0.86 | 0.81 |
| EPS Diluted | 1.56 | 3.93 | 5.99 | 4.60 | 1.26 | 1.29 | 1.18 | 1.16 | 0.99 | 1.09 | 0.86 | 0.81 |
| Weighted Avg Shares Out | 121.86M | 121.78M | 119.42M | 112.13M | 111.08M | 100.46M | 102.21M | 96.44M | 78.79M | 91.20M | 91.20M | 91.20M |
| Weighted Avg Shares Out (Dil) | 121.86M | 122.25M | 119.97M | 112.65M | 111.30M | 100.62M | 102.34M | 96.44M | 78.79M | 91.20M | 91.20M | 91.20M |
Source: https://incomestatements.info
Category: Stock Reports